JP Morgan analyst Arun Jayaram maintains Range Resources (NYSE:RRC) with a Neutral and lowers the price target from $42 to $39.
Bristol-Myers Squibb’s Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Bristol-Myers Squibb Co (NYSE: BMY) announced